SEC Tracker
Get the app

Syndax Pharmaceuticals SNDX

Syndax Pharmaceuticals reported a $49.43 million net loss for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $83.3 million for the three months ended Sep 30, 2026.
  2. Net loss of $49.43 million for the three months ended Sep 30, 2026.
  3. Diluted EPS of -$0.55 for the three months ended Sep 30, 2026.
  4. Cash and equivalents of $135.94 million as of Sep 30, 2026.

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Syndax Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Nurix Therapeutics NRIX public float $808M, May 30, 2025
  2. Niagen Bioscience NAGE public float $814M, Jun 30, 2025
  3. Cogent Biosciences COGT public float $773M, Jun 30, 2025
  4. uniQure QURE public float $765M, Jun 30, 2025
  5. Phibro Animal Health PAHC public float $764M, Dec 31, 2025